

Crohn's Disease Committee meeting

Date: 22/06/2018

Location: London

Minutes: Approved

Committee members present:	
Tessa Lewis (Chair)	(Present for items 1 – 6)
Charmian Banks	(Present for items 1 – 6)
Sarah Cripps	(Present for items 1 – 6)
Jenny Epstein	(Present for items 1 – 6)
Joan Gavin	(Present for items 1 – 6)
Bruce George	(Present for items 1 – 6)
Themba Mudege	(Present for items 1 – 6)
Thomas Mytton	(Present for items 1 – 6)
Robert Palmer	(Present for items 1 – 6)
Megan Prydderch	(Present for items 1 – 6)

In attendance:		
Omnia Abdulrazeg	Technical Analyst	(Present for items 1 – 6)
Chris Carmona	Senior Technical Analyst	(Present for items 1 – 6)
Susannah Gyton-Moon	Programme Manager	(Present for items 1 – 6)
Caroline Keir	NICE - Guideline Commissioning Manager	(Present for items 1 – 6)
Bernadette Li	Technical Advisor – Health Economics	(Present for items 1 – 6)
Rui Martins	Technical Analyst	(Present for items 1 – 6)

Apologies:	
Rachel Cooney	Committee Member
Janindra Warusavitarne	Committee Member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fifth meeting on Ulcerative Colitis and Crohn's Disease. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are

noted above.

The Chair outlined the objectives of the meeting, which included: a discussion of the randomised control trial evidence for Crohn's disease and questions around the health economic model structure for the review question: in adults and children what is the clinical and cost effectiveness of medical and/or nutritional treatment for post-surgical (commencing within three months of any intestinal surgery for Crohn's disease) maintenance of remission for 12 months or longer?

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest the matter under discussion is the clinical and cost effectiveness of medical and/or nutritional treatment for post-surgical (commencing within three months of any intestinal surgery for Crohn's disease).

The Chair asked everyone to verbally declare any interests. The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Presentations – Clinical analysis for Crohn's Disease

The Chair introduced Omnia Abdulrazeg, technical analyst, who set out the approach to the network meta-analysis for Crohn's disease and discussed the initial RCT evidence.

The Committee discussed any issues they thought pertinent to the proposed analysis.

The Chair thanked Omnia for her presentation.

4. Presentations - Crohn's disease economic model structure and assumptions

The Chair introduced Bernadette Li and Rui Martins, health economists, who discussed with the Committee the details of the economic analysis and how the model will be structured.

The Committee discussed any issues they thought pertinent to the proposed analysis and talked about costs and resources they thought should be included in the model.

The Chair thanked Bernadette and Rui for their presentations.

5. AOB

There were no items for AOB.

6. Summary and next steps

Susannah Gyton-Moon, programme manager, informed the Committee that July meeting would be cancelled and that the September meeting would be two days instead of one.

The Chair committee for their attendance and closed the meeting.

Date of next meeting: 25 and 26 September 2018

Location of next meeting: London